About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive Bladder

NCT00224146·10 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Watson Pharmaceuticals

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Adult patients with one or more symptom of overactive bladder, including urge urinary incontinence, urgency and/or frequency

You may not be if

Patients for whom Oxytrol(r) is contraindicated.
Patients treated with Oxytrol(r) prior to participation in this study.
Patients residing in long-term care facilities or nursing homes.

The record

StatusCompleted

PhasePhase 4

Taking part2,878

StartedMay 2004

UpdatedNov 30, 2011

Conditions

Overactive Bladder Urinary Incontinence Quality of Life

Where10

Mobile, Alabama, United States
Tucson, Arizona, United States
Torrance, California, United States

Clareo Health | Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive Bladder